1. Medtech Insight
  2. >>Business
  3. >>Deals

M&A Analysis: Feeble Start To 2017

 
• By Catherine Longworth

2017 kicked off with 12 medtech M&A acquisitions in January, a decline from the 18 M&A deals recorded in the same month last year, and two fewer than the previous month.

Merging Business Network-Business leaders in global agreement
• Source: Shutterstock

While December 2016 rounded off with a final flurry of M&A activity, deal-making shifted down a gear in the first month of the new year. A total of 12 medtech M&A transactions were announced and recorded on Medtech Insight's M&A Data Tracker in January 2017, a decline from the 18 acquisitions in January 2016 and two fewer than December 2016. (Also see " MNA Analysis: 2016 Begins With Small List Highlighted By IVD Blockbuster " - Medtech Insight, 3 February, 2016.)

It continues the year-on-year downward trend in M&A deal volume, with 26 acquisitions tracked in January 2015 and 32 acquisitions...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 
• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 
• By Alaric DeArment

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By Medtech Insight Team

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 
• By Malcolm Spicer

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business

J&J MedTech Launches KINCISE 2 Surgical Automated System In US

 
• By Natasha Barrow

The KINCISE 2 Surgical Automated System aims to “reduce the physical burden on surgeons compared to manual impaction in primary and revision hip and revision knee replacement procedures,” said J&J MedTech.

Quest Diagnostics Minimizes China Tariff Risk With Less Than 1% Supply Chain Exposure

 
• By Shubham Singh

Quest reaffirmed its full-year guidance despite macroeconomic concerns and tariff uncertainty. Revenues are expected between $10.7bn and $10.85bn. Adjusted earnings per share (EPS) is estimated in the $9.55 to $9.80 range for the full year, with EPS between $8.62 and $8.87.

Abbott Launches Next-Gen Delivery System For Proclaim DRG Neurostim

 
• By Shubham Singh

Allen Burton, Abbott’s medical director of neuromodulation told Medtech Insight that the delivery system was developed to make the procedure easier for physicians, especially those who perform the implantations infrequently.